NCT00091130View on ClinicalTrials.gov

SGN-00101 Vaccine in Treating Human Papillomavirus in Patients Who Have Abnormal Cervical Cells

PHASE2CompletedINTERVENTIONAL

Enrollment

139

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

June 30, 2007

Conditions

Atypical Squamous Cells of Undetermined SignificanceCervical CancerHigh-grade Squamous Intraepithelial LesionLow-grade Squamous Intraepithelial Lesion

Interventions

BIOLOGICAL

HspE7

Given SC

OTHER

placebo

Given SC

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

92868

University of California Medical Center At Irvine-Orange Campus, Orange

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH

NCT00091130 - SGN-00101 Vaccine in Treating Human Papillomavirus in Patients Who Have Abnormal Cervical Cells | Biotech Hunter | Biotech Hunter